1. Search Result
Search Result
Results for "

HIF-Α

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

2

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-147025

    PROTACs TGF-beta/Smad HIF/HIF Prolyl-Hydroxylase Inflammation/Immunology
    (S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine is a dual target PROTAC that can not only target to the ubiquitination and degradation of Smad3 but also improve the HIF-α protein level. (S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine has a multi-path anti-fibrosis function and a renal protection function for research of renal anemia .
    (S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine
  • HY-100947
    VH-298
    Maximum Cited Publications
    12 Publications Verification

    Ligands for E3 Ligase HIF/HIF Prolyl-Hydroxylase Inflammation/Immunology Cancer
    VH-298 is a highly potent inhibitor of the VHL:HIF-α interaction with a Kd value of 80 to 90 nM. VH-298 leads to HIF-α accumulation inside HeLa cells. VH-298 is an E3 ligase Ligand, and can be used for synthesis of PROTACs .
    VH-298
  • HY-N0433
    Astragaloside II
    1 Publications Verification

    Astrasieversianin VIII

    Autophagy Interleukin Related HIF/HIF Prolyl-Hydroxylase SOD NF-κB Inflammation/Immunology Endocrinology Cancer
    Astragaloside II is an orally active Cycloartane-type triterpene glycoside. Astragaloside II can be extracted from Astragalus membranaceus. Astragaloside II inhibits Autophagy, decreases pro-inflammatory cytokines (IL-6, IL-1β), HIF-α, p-p65, p-IκB and increases SOD. Astragaloside II regulates immunity and reduces inflammatory responses. Astragaloside II can be used in the research of diseases such as liver cancer, osteoporosis, immunosuppressive diseases, and ulcerative colitis .
    Astragaloside II
  • HY-120110
    IOX4
    5+ Cited Publications

    HIF/HIF Prolyl-Hydroxylase Neurological Disease Inflammation/Immunology
    IOX4 is a selective HIF prolyl-hydroxylase 2 (PHD2) inhibitor with an IC50 value of 1.6 nM, induces HIFα in cells and in wildtype mice with marked induction in the brain tissue. IOX4 competes with and displaces 2-oxoglutarate (2OG) at the active site of PHD2 .
    IOX4
  • HY-B0639
    Amifostine
    5+ Cited Publications

    WR2721

    MDM-2/p53 HIF/HIF Prolyl-Hydroxylase Cancer
    Amifostine (WR2721) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine selectively protects normal tissues from damage caused by radiation and chemotherapy. Amifostine is potent hypoxia-inducible factor-α1 (HIF-α1) and p53 inducer. Amifostine protects cells from damage by scavenging oxygen-derived free radicals. Amifostine reduces renal toxicity and has antiangiogenic action .
    Amifostine
  • HY-B0639A
    Amifostine trihydrate
    5+ Cited Publications

    WR2721 trihydrate

    MDM-2/p53 HIF/HIF Prolyl-Hydroxylase Cancer
    Amifostine trihydrate (WR2721 trihydrate) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine trihydrate selectively protects normal tissues from damage caused by radiation and chemotherapy. Amifostine trihydrate is potent hypoxia-inducible factor-α1 (HIF-α1) and p53 inducer. Amifostine trihydrate protects cells from damage by scavenging oxygen-derived free radicals. Amifostine trihydrate reduces renal toxicity and has antiangiogenic action .
    Amifostine trihydrate
  • HY-112144
    TP0463518
    1 Publications Verification

    HIF/HIF Prolyl-Hydroxylase Metabolic Disease Inflammation/Immunology
    TP0463518 is an orally active, competitive pan-inhibitor of hypoxia-inducible factor prolyl hydroxylases PHD1/2/3. TP0463518 competitively inhibits human PHD1 (IC50=18 nM), PHD2 (Ki=5.3 nM), and PHD3 (IC50=63 nM), and targets monkey PHD2 with an IC50 of 22 nM. TP0463518 inhibits PHD-catalyzed hydroxylation to stabilize HIFα, thereby upregulating erythropoietin (EPO) expression and enhancing intestinal iron absorption (such as increased DMT-1 and dCYTb expression), improving anemia. TP0463518 is mainly used for the research of renal anemia and inflammatory anemia .
    TP0463518
  • HY-N0433R

    Astrasieversianin VIII (Standard)

    Autophagy Interleukin Related HIF/HIF Prolyl-Hydroxylase SOD NF-κB Inflammation/Immunology Endocrinology Cancer
    Astragaloside II (Standard) is the analytical standard of Astragaloside II (HY-N0433). This product is intended for research and analytical applications. Astragaloside II is an orally active Cycloartane-type triterpene glycoside. Astragaloside II can be extracted from Astragalus membranaceus. Astragaloside II inhibits Autophagy, decreases pro-inflammatory cytokines (IL-6, IL-1β), HIF-α, p-p65, p-IκB and increases SOD. Astragaloside II regulates immunity and reduces inflammatory responses. Astragaloside II can be used in the research of diseases such as liver cancer, osteoporosis, immunosuppressive diseases, and ulcerative colitis .
    Astragaloside II (Standard)
  • HY-100947A

    Ligands for E3 Ligase HIF/HIF Prolyl-Hydroxylase Others Inflammation/Immunology Cancer
    cis VH-298 is the cis form of VH-298 (HY-100947). cis VH-298 results in a significant loss of binding specificity of hydroxylated HIF-1a peptides to VHL in vitro .
    cis VH-298
  • HY-155009

    HIF/HIF Prolyl-Hydroxylase Others
    PHD2-IN-1 is a potent and orally active inhibitor of HIF prolyl hydroxylase 2 (PHD2) with an IC50 of 22.53 nM. PHD2-IN-1 can be used for anemia research .
    PHD2-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: